跳至主要内容
临床试验/NCT03212235
NCT03212235Unknown2 期

Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Instituto do Cancer do Estado de São Paulo2 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2017年6月5日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
58
试验地点
2
主要终点
Overall survival

研究概览

简要总结

Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients 18 to 70 years of age with newly diagnosed and histologically confirmed glioblastoma.
  • WHO performance status of 2 or less and adequate hematologic, renal, and hepatic function.

排除标准

  • Prior diagnosis of cancer, unless disease free for > 3 years
  • Previous history of radiotherapy in the head and neck region (except initial larynx tumor - T1, T2 / N0M0).
  • Specific severe, active co-morbidities
  • Tumor located in the brainstem
  • Presence of leptomeningeal carcinomatosis
  • Multicentric tumor

结局指标

主要结局

Overall survival

时间窗: 24 months

From date of the start of treatment to date of death due to any cause.

次要结局

  • Progression-free survival(24 months)

研究者

发起方
Instituto do Cancer do Estado de São Paulo
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gustavo Nader Marta

Radiation Oncologist and Principal Investigator

Instituto do Cancer do Estado de São Paulo

研究点 (2)

Loading locations...

相似试验